Download Protocol

Semaglutide

Semaglutide helps the body feel full faster and use energy more efficiently. It works by helping control appetite and steadying blood sugar levels. People study and use it for managing weight and supporting balanced energy over time.

Description

• Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk.
• It mimics the incretin hormone GLP-1 to regulate blood sugar, reduce appetite, and promote weight loss.
• Clinically approved for the treatment of type 2 diabetes (Ozempic®, Rybelsus®) and chronic obesity (Wegovy®).

How It Works

• Activates GLP-1 receptors in the pancreas and brain to enhance insulin secretion and reduce appetite.
• Delays gastric emptying, leading to prolonged satiety and lower caloric intake.
• Improves glycemic control and promotes gradual, sustainable fat loss.

Documented Effects

• Reduces body weight by 10–15% on average after 68 weeks of therapy in clinical trials.
• Improves HbA1c and fasting glucose in patients with type 2 diabetes.
• Decreases cardiovascular risk factors such as cholesterol and blood pressure.

Theoretical Effects

• May improve metabolic efficiency and energy regulation beyond glucose control.
• Potential neuroprotective and anti-inflammatory properties under study.
• Used off-label in research for weight loss and metabolic optimization.

Pharmacokinetics

• Half-life: approximately 160 hours (~7 days), allowing once-weekly dosing.
• Time to peak plasma concentration: 1–3 days post-injection.
• Steady-state: achieved after 4–5 weeks of continuous use.

Duration of Effects

• Appetite-suppressing and glucose-lowering effects last about 5–7 days per dose.
• Residual metabolic benefits can persist for 2–3 weeks after discontinuation.

Reconstitution

• Use only bacteriostatic water to mix the lyophilized powder.
• Example vial: 10 mg of Semaglutide
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; avoid shaking.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (First-Time Use)

Typical Starting Dose

• Injectable (off-label, clinical research): ~0.25 mg subcutaneous (SC) once weekly.
• Start low to minimize nausea; increase gradually every 4 weeks.

Common Therapeutic Range

• Standard range: 0.25–2.4 mg SC once weekly depending on response.
• Clinical obesity trials use doses up to 2.4 mg weekly for maximum weight reduction.

Maximum Weekly Dose

• Maximum studied dose: 2.4 mg once weekly.
• Higher doses are not supported by safety or efficacy data.

Standard Cycle Length

• Chronic therapy; typically 6–12 months or ongoing for sustained effect.
• Gradual dose escalation prevents side effects and optimizes tolerance.

Clinical Notes

• Inject subcutaneously in the abdomen, thigh, or upper arm; rotate sites weekly.
• Taper gradually when discontinuing to avoid rebound appetite and fatigue.
• Avoid stacking with other GLP-1 or GIP receptor agonists.
• Stable for about 30 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes (First-Time Use)

• Begin with 0.25 mg weekly for 4 weeks, then titrate upward.
• Common side effects: nausea, mild constipation, reduced appetite.
• Avoid combining with other GLP-1 receptor agonists.
• Contraindicated in patients with MEN2 or medullary thyroid carcinoma history.
• Long-term safety is supported in multi-year clinical studies.